Skip to main content
lung%2Cbright.jpg

Cytokine Inhibitor Lung Disease in Still's Linked to HLA-DRB1 Alleles

Dec 01, 2021

Pulmonary complications in the setting of Still's disease (juvenile and adult) has seldom but consistently been reported, including reports of pneumonitis, pulmonary hypertension and a severe or fatal lung disease, often associated with hypersensitivity to anticytokine therapy. A multicenter

Read Article
bathroom scale

The Influence of Obesity on Choice of Biologic in Rheumatoid Arthritis

In rheumatoid arthritis we have a wide range of options available to us when we progress to a biologic treatment option. We have little to differentiate between these agents based on the clinical trials. We often make our choices based on minor hints from clinical features, comorbidities, or

Read Article
Giant-Cell_Vasculitis.jpg

Top vasculitis takeaways from ACR 2021

There were several hot topics at ACR21. Here I concentrate on top abstracts in vasculitis. 

Read Article
FDA Update: 3 trials showing Efficacy of Tocilizumab in COVID 19: 1. RECOVERY - lower mortality 2. EMPACTA - Less progression to mech vent or death 3. REMDACTA & COVACTA - did not meet primary endpoints (but not contradictory) FDA Metanalysis of all 4 trials #ACR21 EUA 6/21 https://t.co/9yHu87KGej
Dr. John Cush @RheumNow( View Tweet )
Nov 08, 2021
TCZ in GCA: one disadvantage is that you can't use CRP+/- ESR for flares Mavrilimumab in GCA: - CRP/ESR consistently go up with symptomatic flares - CRP/ESR up less (cf. placebo), in the absence of Sx flares More signal, less noise. phase 2 post-hoc #ACR21 ABST1401 @RheumNow https://t.co/c0lMJMcQv0
Nov 08, 2021
NORD-STAR Trial: outcomes in tx-naïve, early RA pts after 48w of csDMARDs+GC vs bDMARD (ABAtacept, CerToliZumab, or ToCiluZumab)+MTX ➡️ Superior CDAI remission rates w/ ABA+MTX & CZP+MTX but not TCZ+MTX vs csDMARD+GC ➡️Imaging progression low in all Abst#0825 #ACR21 @RheumNow https://t.co/QaFIF4WNEG
Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )
Nov 07, 2021
#ACR21 Abs#0834: CorEvitas Registry TNFi vs IL-6 in RA ⭐️IL6 pts older, longer h/o RA, higher CDAI, more prior Rx ▶️ No difference in outcomes bw IL6 and TNFi (monotherapy or combo w MTX). ▶️1/3 of pts achieved LDA Limits: real-world, unblindedhttps://t.co/AJtzeMuj1T @Rheumnow
Nov 07, 2021
bathroom scale

The Influence of Obesity on Choice of Biologic Agent in Rheumatoid Arthritis

In rheumatoid arthritis we have a wide range of options available to us when we progress to a biologic treatment option. We have little to differentiate between these agents based on the clinical trials. We often make our choices based on minor hints from clinical features, comorbidities, or

Read Article
ADACTA & MONARCH both showed IL6i monoRx > TNFi monoRx for RA in DBRCTs. What about in real-world data? Looking at CorEvitas, less so LDA: aOR 0.99 MCID in CDAI: 1.06 Even without MTX, both great drug classes for RA Equally so? #ACR21 ABST0834 @RheumNow https://t.co/6wvzVrXTW6 https://t.co/fYEktJhZuV
Nov 07, 2021
It's all happening for biologic therapies in PMR! phase 2/3 double-blind RCT: - new PMR - n=36 - 11w PNL taper (until relapse - clinical not lab) - weekly sc TCZ for 16w vs placebo big benefit persists post-TCZ cessation real steroid sparing PMR-SPARE #ACR21 ABST0507 @RheumNow https://t.co/w8tgOPAtyJ
Nov 06, 2021
In GCA, why might you target GM-CSF over IL-6? Entirely plausible TCZ might be leaving some Th1 stones unturned, esp: vascular remodelling downreg pathways Transcriptomics from toci/mavri-treated TAB show it's plausible beyond just theory... Cid group #ACR21 ABST0506 @RheumNow https://t.co/YephlzHOdj
Nov 06, 2021
Gender differences in AS pts? IL-23R, IL-12R, IL-6R, JAK, STAT and TYK2 ⬇️regulated in men Small study of 20 pts, but could it guide targeted therapy based on gender?🤔 Abs#0050https://t.co/OQHQCCzfuC#ACR21 @RheumNow

Robert B Chao, MD @doctorRBC( View Tweet )

Nov 06, 2021
#ACR21 Abst#0269 ⭐️TCZ: ⬆️cholesterol, LDL, TG. ⬇️ hsCRP compared to TNFi. No ⬆️ risk of Reynold risk score (RRS) Take-away: good data on TCZ effect on lipids, but I wouldn't use RRS to calculate CVD risk on med that ⬇️ CRP @Rheumnow https://t.co/zMltktfHkS https://t.co/bwKXiGIi8a
Nov 06, 2021
×